Discover trends, market shifts, and competitive outlooks for the gastroparesis drugs industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What is the Anticipated CAGR of the Gastroparesis Drugs Market, and What Factors Will Drive It?

In recent times, the market size for gastroparesis drugs has seen substantial growth. The market, which stood at $5.39 billion in 2024, is forecasted to increase to $5.73 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.3%. The observed growth in the past period is a result of various factors such as the side effects of current treatments, research in gastrointestinal motility, clinical demand, patient advocacy efforts, and regulatory backing.

The market size for gastroparesis drugs is predicted to experience a significant expansion in the coming years, reaching $7.2 billion by 2029 with a compound annual growth rate (CAGR) of 5.9%. This growth during the forecast period is attributed to factors such as the rising prevalence of diabetes, an aging population, increased awareness and diagnostic capabilities, growth in healthcare spending, and financial support from both governmental and private entities. The forecast period is also expected to be influenced by key trends including breakthroughs in gastroenterology, enhanced diagnostic methods, technological advances, increased funding for research, and cooperative research endeavors.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

What Are the Core Market Drivers Propelling Growth in the Gastroparesis Drugs Industry?

The escalating incidents of diabetes are predicted to fuel the expansion of the gastroparesis drugs market in the future. Diabetes manifests as a continual health problem characterized by elevated blood sugar levels arising from insufficient insulin production or the body’s ineffectual use of insulin. The mounting incidents of diabetes can be attributed to inactive lifestyles, poor eating habits, genetic susceptibility, urbanization, and an aging demographic, exacerbated by limited healthcare accessibility and the global rise in obesity rates. Gastroparesis medications are often administered to diabetic patients to mitigate symptoms such as nausea, vomiting, and slow gastric emptying, which are typical diabetes complications that affect the function of the gut. These treatments aim to enhance gastric activity and boost the quality of life for people suffering from diabetes-induced gastroparesis. For example, in March 2024, the Office for Health Improvement & Disparities, a governmental department based in the UK, reported that between March 2022 and March 2023, the proportion of individuals with type 1 diabetes undergoing all eight suggested care processes climbed by 22%, and for type 2 diabetes, it escalated by 21%. Simultaneously, the percentage accomplishing target HbA1c levels advanced to 37.9%, a record high reported by the National Diabetes Audit (NDA). Consequently, the climbing incidents of diabetes are propelling the growth of the gastroparesis drugs market.

What Segment Types Define the Gastroparesis Drugs Market Structure?

The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:

1) Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements

2) Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=15812&type=smp

Which Regions Are Driving the Next Phase of the Gastroparesis Drugs Market Growth?

North America was the largest region in the gastroparesis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which Emerging Trends that Are Influencing the Gastroparesis Drugs Industry Evolution?

To gain an advantage in the gastroparesis drugs sector, leading corporations are focusing on the development and launch of innovative medicines like Gimoti (metoclopramide) nasal spray. This medication, which treats gastroparesis symptoms in adults by speeding up the emptying of the stomach through improved gastrointestinal motility, is absorbed directly into the bloodstream via the nasal mucosa, bypassing the gastrointestinal tract. For example, Evoke Pharma Inc., an American pharmaceutical firm, announced in April 2022 that it had secured new drug product exclusivity for GIMOTI (metoclopramide) nasal spray from the U.S. Food and Drug Administration (FDA). Under the Hatch-Waxman Act, this exclusivity grants Evoke sole marketing rights for the product for a period of three years from the initial authorization date, shielding it from generic market rivals.

View the full report here:

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

What Is the Definition of the Gastroparesis Drugs Market?

Gastroparesis drugs are medications used to manage and treat gastroparesis, a condition where the stomach’s ability to empty its contents is delayed, causing symptoms such as nausea, vomiting, and abdominal pain. These drugs typically include prokinetics to stimulate stomach motility, antiemetics to control nausea and vomiting, and medications to manage pain and other symptoms associated with the condition.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15812

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model